Individual approach in treatment of advanced stomach cancer

Title:

Individual approach in treatment of advanced stomach cancer
Individual approach in treatment of advanced stomach cancer

Creator:

Juraev, M. D., Egamberdiev, D. M., Khudayorov, S. S., and Tuyev, H. N.

Contributor:

Juraev, M. D., Egamberdiev, D. M., Khudayorov, S. S., and Tuyev, H. N.

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc14045867-a54005da-7bc2-42fb-bc70-c75844eb7e9f
uuid:bmc14045867-a54005da-7bc2-42fb-bc70-c75844eb7e9f
local:bmc14045867
http://ojs.journals.cz/index.php/EMHPJ/issue/archive
local: bmc14045867

Subject:

nádory žaludku--terapie, exprese genu, receptor erbB-2--účinky léků, monoklonální protilátky--aplikace a dávkování--terapeutické užití, chemoterapie adjuvantní, výsledek terapie, and lidé

Type:

model:article, article, Text, statistics, and TEXT

Format:

braille, electronic resource, remote, and elektronický zdroj

Description:

To study efficiency of the combined treatment of advanced gastric cancer with inclusion Trastuzumab. Material: We present the intermediate analysis of the use of target therapy with Trastuzumab in patients with a HER2positive gastric cancer. Up to 01.10.2009y 118 patients have been tested for HER2 expression, and in 24 gastric cancer patients it is revealed HER2positive status of tumor. It is lead chemotherapy to all patients by the PLF regimen and Herceptin in doze 6 mg/kg once in 3 weeks (6 cycles). In control group in 26 patients it is lead only chemotherapy by the PLF regimen once in 3 weeks without addition Trastuzumab (6 cycles). Results: At the moment of the analysis of preliminary data, the median remission duration in compared groups has made 8.3 months, and 5.2 months, accordingly. Conclusion: At advanced gastric cancer with high level HER2 expression Trastuzumab increases frequency of objective effect and the median remission duration., M. D. Juraev, D. M. Egamberdiev, S. S. Khudayorov, H. N. Tuyev, and Literatura

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

European medical, health and pharmaceutical journal--MED00177703

Source:

European medical, health and pharmaceutical journal : open access reviewed journal | 2010 Volume:2010 | Number:1

Harvested from:

CDK

Metadata only:

false

Date:

2010